A 36 month multi-centre clinical trial of using prophylactic azithromycin in adults with primary antibody deficiencies with chronic respiratory pathologies such as bronchiectasis, COPD, asthma and recurrent hospital admissions found that there was significant benefit and reduced exacerbations of their respiratory infections and hospitalisations and improved quality of life. The trial azithromycin dosage was 250mg three times per week administered on 3 consecutive days of the week for 36 months. Side effects and opportunistic infections were also negligible and the treatment was well tolerated.
Reference: American Association for Asthma, Allergy and Immunology. https://www.aaaai.org/global/latest-research-summaries/Current-JACI-Research/azithromycin
